Cullinan Therapeutics Hits New 52-Week Low at $6.32

Cullinan Therapeutics, Inc., a player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 6.32 on September 15, 2025. This significant decline marks a stark contrast to the stock's 52-week high of USD 18.62, reflecting a year-to-date performance drop of 72.36%.
The company's market capitalization stands at USD 404 million, indicating its position within the industry. Cullinan Therapeutics is currently operating at a loss, as evidenced by its negative price-to-earnings ratio, while the industry average remains unavailable. The firm also shows a return on equity of -42.01%, suggesting challenges in generating profit from its equity base.

Additionally, the company has a price-to-book ratio of 0.82, which may indicate that the stock is trading below its book value. With a debt-to-equity ratio of -0.54, Cullinan Therapeutics appears to have a unique financial structure. The absence of a dividend yield further emphasizes its focus on growth rather than returning capital to shareholders.